{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:43:28Z","timestamp":1786221808558,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jns.2026.126092","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:37:44Z","timestamp":1783528664000},"page":"126092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Long-term treatment with Eptinezumab in special treatment situations: Real world data"],"prefix":"10.1016","volume":"489","author":[{"given":"Berit","family":"H\u00f6fer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Koschatzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Sabatowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thea","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Klimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Gossrau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2026.126092_bb0005","series-title":"Migraine and tension-type headache in Germany. Prevalence and Disease Severity From the BURDEN 2020 Burden of Disease Study","author":"Porst","year":"2020"},{"issue":"12","key":"10.1016\/j.jns.2026.126092_bb0010","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S1474-4422(25)00402-8","article-title":"Global, regional, and national burden of headache disorders, 1990\u20132023: a systematic analysis for the global burden of disease study 2023","volume":"24","author":"Hus\u2298y","year":"2025","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.jns.2026.126092_bb0015","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ana.410230214","article-title":"Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system","volume":"23","author":"Goadsby","year":"1988","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2026.126092_bb0020","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00281-018-0676-y","article-title":"Neurogenic inflammation and its role in migraine","volume":"40","author":"Ramachandran","year":"2018","journal-title":"Semin. Immunopathol."},{"issue":"11","key":"10.1016\/j.jns.2026.126092_bb0025","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jpain.2013.03.010","article-title":"Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system","volume":"14","author":"Eftekhari","year":"2013","journal-title":"J. Pain"},{"issue":"1","key":"10.1016\/j.jns.2026.126092_bb0030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s10194-019-1055-3","article-title":"C-fibers may modulate adjacent A\u03b4-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system","volume":"20","author":"Edvinsson","year":"2019","journal-title":"J. Headache Pain"},{"issue":"5","key":"10.1016\/j.jns.2026.126092_bb0035","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/head.13529","article-title":"CGRP and the trigeminal system in migraine","volume":"59","author":"Iyengar","year":"2019","journal-title":"Headache"},{"issue":"2","key":"10.1016\/j.jns.2026.126092_bb0040","doi-asserted-by":"crossref","DOI":"10.1177\/03331024251320608","article-title":"Setting higher standards for migraine prevention: a position statement of the international headache society","volume":"45","author":"Sacco","year":"2025","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.jns.2026.126092_bb0045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","article-title":"European headache federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention \u2013 2022 update","volume":"23","author":"Sacco","year":"2022","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.jns.2026.126092_bb0050","series-title":"Therapie der Migr\u00e4neattacke und Prophylaxe der Migr\u00e4ne: Entwicklungsstufe: S1. DMKG und DNG, Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie","author":"Diener","year":"2022"},{"issue":"S2","key":"10.1016\/j.jns.2026.126092_bb0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/head.13582","article-title":"Targeting CGRP and 5-HT1F receptors for the acute therapy of migraine: a literature review","volume":"59","author":"Moreno-Ajona","year":"2019","journal-title":"Headache"},{"issue":"11","key":"10.1016\/j.jns.2026.126092_bb0060","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1358\/dot.2019.55.11.3069864","article-title":"Eptinezumab for the treatment of migraine","volume":"55","author":"Scuteri","year":"2019","journal-title":"Drugs Today (Barc)"},{"issue":"3","key":"10.1016\/j.jns.2026.126092_bb0065","doi-asserted-by":"crossref","DOI":"10.1177\/03331024241238153","article-title":"Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex","volume":"44","author":"Porreca","year":"2024","journal-title":"Cephalalgia"},{"issue":"12","key":"10.1016\/j.jns.2026.126092_bb0070","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70460","article-title":"Early and sustained shift in headache day frequency following Eptinezumab treatment in adults with migraine for whom 2\u20134 previous preventive treatments have failed: a post hoc analysis of the randomized DELIVER trial","volume":"32","author":"Tassorelli","year":"2025","journal-title":"Eur. J. Neurol."},{"issue":"24","key":"10.1016\/j.jns.2026.126092_bb0075","doi-asserted-by":"crossref","first-page":"8793","DOI":"10.3390\/jcm14248793","article-title":"Testing the efficacy of Eptinezumab 100 mg in the early prevention of chronic migraine over weeks 1 to 4: prospective real-world data from the GRASP study group","volume":"14","author":"Argyriou","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jns.2026.126092_bb0080","author":"Gobel"},{"issue":"2","key":"10.1016\/j.jns.2026.126092_bb0085","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"PAIN"},{"issue":"1","key":"10.1016\/j.jns.2026.126092_bb0090","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s10194-022-01447-3","article-title":"The headache registry of the German migraine and headache society (DMKG): baseline data of the first 1,351 patients","volume":"23","author":"Ruscheweyh","year":"2022","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.jns.2026.126092_bb0095","series-title":"R A Language and Environment for Statistical Computing","author":"R Core Team","year":"2023"},{"issue":"5","key":"10.1016\/j.jns.2026.126092_bb0100","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/00207454.2022.2115906","article-title":"Efficacy and safety of eptinezumab 300mg versus 100mg for migraine patients: A meta-analysis of randomized controlled studies","volume":"134","author":"Chen","year":"2024","journal-title":"Int. J. Neurosci."},{"issue":"1","key":"10.1016\/j.jns.2026.126092_bb0105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s10194-024-01764-9","article-title":"Real-world effectiveness and satisfaction with intravenous eptinezumab treatment in patients with chronic migraine: REVIEW, an observational, multi-site, US-based study","volume":"25","author":"Argoff","year":"2024","journal-title":"J. Headache Pain"},{"issue":"1","key":"10.1016\/j.jns.2026.126092_bb0110","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-024-01788-1","article-title":"Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre retrospective real-world analysis from Germany","volume":"25","author":"Scheffler","year":"2024","journal-title":"J. Headache Pain"},{"issue":"7","key":"10.1016\/j.jns.2026.126092_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci14070672","article-title":"Evaluating the effectiveness, tolerability, and safety of eptinezumab in high-frequency and chronic migraine in real world: EMBRACE-the first Italian multicenter, prospective, real-life study","volume":"14","author":"Barbanti","year":"2024","journal-title":"Brain Sci."},{"issue":"5","key":"10.1016\/j.jns.2026.126092_bb0120","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s40120-023-00521-5","article-title":"Effectiveness and safety of Eptinezumab in episodic and chronic migraine headache in the UAE: A retrospective study","volume":"12","author":"Bader","year":"2023","journal-title":"Neurol. Ther."},{"issue":"7","key":"10.1016\/j.jns.2026.126092_bb0125","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/head.14737","article-title":"A real-world prospective observational study of eptinezumab in Asian patients with migraine","volume":"64","author":"Zhao","year":"2024","journal-title":"Headache"},{"issue":"1","key":"10.1016\/j.jns.2026.126092_bb0130","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/head.70015","article-title":"A retrospective audit of the real-world safety and effectiveness profile of eptinezumab for treatment-resistant chronic migraine in Australia","volume":"66","author":"Gunasekera","year":"2026","journal-title":"Headache"},{"issue":"1","key":"10.1016\/j.jns.2026.126092_bb0135","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s10194-025-02180-3","article-title":"A prospective real-world analysis of intravenous eptinezumab in migraine management: the first UK experience","volume":"26","author":"Andreou","year":"2025","journal-title":"J. Headache Pain"},{"issue":"6","key":"10.1016\/j.jns.2026.126092_bb0140","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-025-13095-z","article-title":"A 24-week prospective, multicenter, real-world study on eptinezumab's effectiveness and safety in migraine prevention (EMBRACE II)","volume":"272","author":"Barbanti","year":"2025","journal-title":"J. Neurol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26003746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26003746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:08:27Z","timestamp":1786219707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26003746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":28,"alternative-id":["S0022510X26003746"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.126092","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term treatment with Eptinezumab in special treatment situations: Real world data","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.126092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"126092"}}